"As yet, there is no survival advantage known for use of an aromatase inhibitor vs tamoxifen among postmenopausal women. Thus, the data from the ATAC trial are provocative and may yet demonstrate long-term superiority vs tamoxifen, but they are currently not definitive yet. A particular concern is the lack of long-term follow-up for both efficacy and safety. While aromatase inhibitors are generally well tolerated, there are concerns about late side effects, including the possibility of osteoporosis, which may be significant in women with very favorable breast cancer prognoses." Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.